Vitruvian Partners’s MaxCyte MXCT Stock Holding History

Vitruvian Partners’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.54M	Hold	5,043,356	–	–	3.17%	6
2025 Q4	$7.82M	Hold	5,043,356	–	–	5.62%	6
2025 Q3	$7.97M	Hold	5,043,356	–	–	5.53%	5
2025 Q2	$11M	Hold	5,043,356	–	–	6.7%	4
2025 Q1	$13.8M	Hold	5,043,356	–	–	13.13%	3
2024 Q4	$21M	Hold	5,043,356	–	–	18.06%	3
2024 Q3	$19.6M	Hold	5,043,356	–	–	7.62%	4
2024 Q2	$19.8M	Hold	5,043,356	–	–	5.8%	5
2024 Q1	$21.1M	Hold	5,043,356	–	–	6.7%	5
2023 Q4	$23.7M	Hold	5,043,356	–	–	6.02%	6
2023 Q3	$15.7M	Hold	5,043,356	–	–	4.46%	6
2023 Q2	$23.1M	Hold	5,043,356	–	–	4.71%	6
2023 Q1	$25M	Hold	5,043,356	–	–	5.33%	5
2022 Q4	$27.5M	Hold	5,043,356	–	–	5.8%	5
2022 Q3	$32.8M	Hold	5,043,356	–	–	5.85%	5
2022 Q2	$23.9M	Buy	5,043,356 +657,686	+15%	+$3.24M	4.05%	7
2022 Q1	$30.7M	Buy	4,385,670 +1,055,670	+32%	+$7.21M	3.25%	7
2021 Q4	$33.9M	Hold	3,330,000	–	–	1.77%	6
2021 Q3	$40.7M	Buy	+3,330,000	New	+$50.2M	1.7%	5

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CFM

Capricorn Fund Managers London, United Kingdom $641M AUM 61.79% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $88.9M AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vitruvian Partners's MXCT Position: Q1 2026 in Review

Vitruvian Partners held its MaxCyte (MXCT) position steady in Q1 2026 at 5,043,356 shares worth $3.54M. The position accounts for 3.17% of the portfolio, ranked #6.

Vitruvian Partners first reported a position in MXCT in Q3 2021 and has held it in 19 quarters since. The position peaked at $40.7M in Q3 2021. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

Vitruvian Partners held 5,043,356 shares of MaxCyte worth $3.54M as of Q1 2026.
Vitruvian Partners left its MaxCyte share count unchanged in Q1 2026.
MaxCyte made up 3.17% of Vitruvian Partners's portfolio in Q1 2026, its #6 holding.
Vitruvian Partners first reported a position in MaxCyte in Q3 2021 and has held it in 19 quarters since.
Vitruvian Partners's MaxCyte position peaked at $40.7M in Q3 2021.
130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Vitruvian Partners's 13F filing for Q1 2026, filed 11 May 2026.